Lovastatin is hypertriglyceridemic in Syrian golden hamsters

Area of Science:

• Biochemistry
• Pharmacology
• Metabolic research

Background:

• HMG CoA reductase inhibitors, like lovastatin, are used to lower cholesterol.
• The immediate and long-term effects of lovastatin on lipid metabolism in hamsters are not fully understood.

Purpose of the Study:

• To investigate the impact of lovastatin on serum triglyceride and cholesterol levels in male Syrian Golden hamsters.
• To explore the role of mevalonate in mediating the effects of lovastatin.

Main Methods:

• Male Syrian Golden hamsters were fed a diet containing 0.1% lovastatin for varying durations.
• Serum triglyceride and cholesterol levels were measured.
• Hepatic cholesterol synthesis was assessed using [14C]cholesterol.
• Experiments included co-administration of lovastatin and Na-mevalonate.

Main Results:

• Short-term lovastatin treatment (6 days) caused a 12-fold increase in serum triglycerides and a 2.4-fold increase in serum cholesterol.
• Continuous lovastatin administration led to a gradual decrease in triglyceride and cholesterol levels, falling below control values by 12-18 days.
• Co-administration with Na-mevalonate prevented the increase in serum triglycerides.
• Hepatic [14C]cholesterol synthesis increased 266-fold after 6 days of lovastatin treatment.

Conclusions:

• Lovastatin significantly impacts hamster lipid profiles, with an initial rise followed by normalization.
• Increased endogenous mevalonate metabolite synthesis may explain the normalization of triglyceride levels.
• Mevalonate metabolites are suggested to be essential for normal triglyceride metabolism in hamsters.